Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 2353 • ACR Convergence 2025
Efficacy of Vunakizumab in Reducing Pain in Ankylosing Spondylitis: A Post-Hoc Analysis of a Phase 2/3 Clinical Trial
Jian Xu, Yifan Yang, Shuang Liu, Ru Bai, Shu Li, Guofang Zhang, Xiangyu Wang, Xinyu Xu, Mai Zheng and Daying Feng, The First Affiliated Hospital of Kunming Medical University, Kunming, China (People's Republic)
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the spine and sacroiliac joints, resulting in significant pain, stiffness, and functional impairment.…
Abstract Number: 1754 • ACR Convergence 2025
B3GNT2 Regulates Integrin β3 Glycosylation and Th17/Treg Imbalance in Axial Spondyloarthritis Pathogenesis
Chengchun Geng¹, Dachun Zhuo¹, Jiucun Wang² and Jing Liu¹, ¹Fudan University, Shanghai, Shanghai, China (People's Republic), ²Fudan University, Shanghai, China (People's Republic)
Background/Purpose: The rs6759298 variant near B3GNT2 is associated with Axial Spondyloarthritis (AS); however, its pathogenic mechanisms remain unknown. In this study, we explored the role…
Abstract Number: 1433 • ACR Convergence 2025
Identifying Predictors of Difficult-to-Manage Axial Spondyloarthritis: Real-World Insights from a Taiwanese Registry Cohort
Yen-An Chang and Ming-Han Chen, Division of Allergy, Immunology & Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, Taipei, Taiwan (Republic of China)
Background/Purpose: The concept of Difficult-to-Manage Axial Spondyloarthritis (D2M-ax-SpA) was recently introduced by the Assessment of Spondyloarthritis International Society (ASAS). According to this new definition, D2M-ax-SpA…
Abstract Number: 0554 • ACR Convergence 2025
Real world experience with generic Tofacitinib in Axial Spondyloarthritis from North India
Sanjeev Kapoor¹, Babita Bondage¹, Niti Kedia¹, Mariya Patel¹ and Akanksha Kapoor², ¹Indian Spinal Injuries Centre (ISIC), New Delhi, India, ²Bharati Vidyapeeth (Deemed to be University) Medical College and Hospital, Pune, India
Background/Purpose: Axial spondyloarthritis (AxSpA) is an inflammatory condition that falls under the category of spondyloarthritis (SpA) and significantly affects quality of life, causing symptoms like…
Abstract Number: 0098 • ACR Convergence 2025
The Deubiquitinase TRABID is a Regulator of Osteogenesis and Inflammation in Spondyloarthritis:
Archita Srinath¹, Sungsin Jo², Daniele Mauro³, Mariia Korshko⁴, Mansi Aparnathi⁵, Shaghayegh Foroozan Boroojeni⁶, Tae-Hwan Kim⁷, Francesco Ciccia⁸ and Nigil Haroon⁹, ¹University of Toronto, Toronto, ON, Canada, ²Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ³University of Campania, Italy, Naples, Italy, ⁴UHN, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ⁶University Health Network/University of Toronto, Toronto, ON, Canada, ⁷Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁸University of Campania, Naples, Italy, ⁹Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada
Background/Purpose: Axial Spondyloarthritis (AxSpA) is characterized by both inflammation and new bone formation. Current therapeutic targets aim to control inflammation, however over 40% of patients…
Abstract Number: 2346 • ACR Convergence 2025
Back in Action: Six Months of Biological Therapy Improve Sexual Function in Men with Ankylosing Spondylitis
Daniel Zavada¹, Barbora Vala², Adela Navratilova², Veronika Losterova², Lenka Moravcova², Jiri Vencovsky³, Ladislav Šenolt⁴, Karel Pavelka⁵ and Michal Tomcik⁵, ¹Institute of Rheumatology, Prague; Charles University, Third Faculty of Medicine, Hlavné mesto Praha, Czech Republic, ²Institute of Rheumatology, Praha, Czech Republic, ³Institute of Rheumatology, Praha ⁸, Czech Republic, ⁴Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁵Institute of Rheumatology and Department of Rheumatology, ¹st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Ankylosing spondylitis (AS) significantly impacts quality of life across multiple domains. To date, no studies have evaluated the impact of initial biological therapy on…
Abstract Number: 1752 • ACR Convergence 2025
Prg4+ Ligament Cells Are Involved in Ligament Ossification in Ankylosing Spondylitis
Kunhai Tang¹, Lilu Zu¹, Chenyuan Wu¹, Jiucun Wang¹ and Jing Liu², ¹Fudan University, shanghai, China (People's Republic), ²Fudan University, Shanghai, Shanghai, China (People's Republic)
Background/Purpose: Ankylosing spondylitis(AS) is a chronic inflammatory disease with clinical symptoms characterized by inflammatory low back pain and spinal ankylosis due to ligament ossification. Enthesitis…
Abstract Number: 1429 • ACR Convergence 2025
Survival Outcomes in Elderly Patients with Axial Spondyloarthritis and Concomitant Cancer
Savannah Bowman¹, Mei Li², Xiudong Lei³, Hui Zhao³, Juan Ruiz⁴, Sharon H. Giordano³, Alexis Ogdie⁵ and Maria Suarez-Almazor⁶, ¹Baylor College of Medicine, Houston, ²The University of Texas Health Science Center at Houston, Houston, ³The University of Texas MD Anderson Cancer Center, Houston, ⁴Hospital Alemán, Buenos Aires, Argentina, ⁵University of Pennsylvania, Philadelphia, PA, ⁶MD Anderson Cancer Center, Houston, TX
Background/Purpose: Axial spondyloarthritis (axSpA) is associated with several comorbidities, including cancer. Prior studies have shown that elderly patients with rheumatoid arthritis and concomitant breast or…
Abstract Number: 0553 • ACR Convergence 2025
Modified A-Tool: An online self-screening tool for axial spondyloarthritis for patients with chronic back pain
Zeyu Tang¹ and Abhijeet Danve², ¹Yale School of Medicine, New Haven, CT, ²Section of Rheumatology, Department of Medicine, Yale School of Medicine, New Haven, CT
Background/Purpose: Lack of timely rheumatology referral of chronic back pain (CBP) patients with suspected axial spondyloarthritis (axSpA) is a major contributor to delayed diagnosis. We…
Abstract Number: 2347 • ACR Convergence 2025
Bimekizumab Treatment Resulted in Patients with Axial Spondyloarthritis Maintaining Their Clinical Responses Over 3 Years: Results from Two Phase 3 Studies and Their Open-Label Extension
Fabian Proft¹, Désirée Van Der Heijde², Sergio Schwartzman³, Vanessa Taieb⁴, Sarah Kavanagh⁵, Gaëlle Varkas⁶, Victoria Navarro-Compan⁷ and Xenofon Baraliakos⁸, ¹Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Weill Cornell Medical Center, New York Presbyterian Hospital, and Hospital for Special Surgery, New York, NY, ⁴UCB, Colombes, France, ⁵UCB, Morrisville, NC, ⁶Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ⁷Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ⁸Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease which requires optimal management.1 In clinical trials, Assessment of SpondyloArthritis international Society ≥40% improvement (ASAS40) is…
Abstract Number: 1715 • ACR Convergence 2025
Spondyloarthritis and Psoriatic Arthritis Patients Under Immunosuppressive Conventional and Biologic DMARDs: Favorable Disease Safety and Attenuated Immunogenicity Following Recombinant Herpes Zoster Vaccination
Carla Saad¹, Eduardo Borba², Fernanda Chaer³, Ana C Medeiros-Ribeiro¹, Sandra G Pasoto¹, Nadia Emi Aikawa⁴, Luisa Correia⁵, Percival Sampaio-Barros⁶, Julio Moraes⁷, Murillo Dorio¹, Claudia Goldenstein-Schainberg¹, Clovis Artur Silva⁸ and Eloisa Bonfa², ¹Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ²Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, ³Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Santos, Brazil, ⁴Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, São Paulo, Brazil, ⁵Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, ⁶Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, Brazil, ⁷Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Jundiai, Brazil, ⁸University of São Paulo, São Paulo, São Paulo, Brazil
Background/Purpose: Psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) patients are at increased risk for herpes zoster(HZ) due to impaired cell-mediated immunity associated with the underlying…
Abstract Number: 1428 • ACR Convergence 2025
Ankylosing Spondylitis Related Mortality Trends in USA from 1999-2020: Analysis of CDC Wonder Database
Sanjana Thimmannagari¹, Shiamak Cooper², Asim Khanfar¹ and Candrika Dini Khairani¹, ¹Rochester General Hospital, Rochester, NY, ²Rochester General Hospital, Irondequoit, NY
Background/Purpose: Ankylosing spondylitis is a significant cause of mortality and morbidity in the United States (US), with a prevalence of 0.2%–0.5%. However, trends in mortality…
Abstract Number: 0888 • ACR Convergence 2025
TargetScan Platform Identifies Targets of CD8+ T cells in Ankylosing Spondylitis and Birdshot Uveitis
Adam S. Weinheimer¹, Olivia Pryor², Catalina Burbano³, Tyler Heath³, Livio Dukaj³, Shoshana M.K. Bloom³, Jackson Lirette³, Rachel Lent³, Prachi Dhanania³, Nicole A. Ladd³, Ryan Kritzer³, Hana Husic³, Shobitha Jillella³, Alexander Cristofaro², Chandan K. Pavuluri³, Jenna LaBelle³, Laurie Barefoot³, Shrikanta Chattopadhyay³, Andrew P. Ferretti³ and Cagan Gurer³, ¹TScan Therapeutics, Boston, MA, ²TScan Therapeutics, Waltham, ³TScan Therapeutics, Waltham, MA
Background/Purpose: Antigen-specific therapies offer a promising approach to selectively modulating autoimmune responses without broad immunosuppression. Strong associations with specific Class I HLA alleles in ankylosing…
Abstract Number: 2337 • ACR Convergence 2025
A Mediation Analysis of Tofacitinib’s Effects on SF-36: The Roles of Fatigue, Pain, Stiffness, and Mobility in Ankylosing Spondylitis
Xenofon Baraliakos¹, Andrew G. Bushmakin², Joseph C. Cappelleri², Eleni Nikitopoulou³, You-Li Ling⁴, Mostafa Zayed⁵ and Jonathan Dominick Cicci⁶, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ²Pfizer Inc., Groton, CT, ³Pfizer Hellas, Athens, Greece, ⁴Pfizer Inc, New York, NY, USA, New York, NY, ⁵Pfizer Gulf FZ LLC, Dubai, United Arab Emirates, ⁶Pfizer Inc., New York, NY
Background/Purpose: Mediation modeling is used to determine mechanisms underlying the relationship between independent and dependent variables via other explanatory variables (“mediators”). Fatigue, pain, and morning…
Abstract Number: 1673 • ACR Convergence 2025
Is Transient Synovitis of the Hip preclinical Juvenile SpA ? A follow-up study
Anirudh Bandu¹, Michal Cidon² and Michael Weisman³, ¹CHLA, Los Angeles, NJ, ²Children's Hospital of Los Angeles, Los Angeles, CA, ³Cedars-Sinai Medical Center, LOS ANGELES, CA
Background/Purpose: Transient synovitis (TS) of the hip is considered a common, self-limited condition in the pediatric population. However, recurrences can occur; these may signal an…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].